ID: ALA5204892

Max Phase: Preclinical

Molecular Formula: C41H53N7O5

Molecular Weight: 723.92

Associated Items:

Representations

Canonical SMILES:  CN(C(=O)C1CCN(C(=O)N[C@@H](CC(=O)NCC(C)(C)C)C(=O)N[C@@H](CCc2ccccc2)C(=O)N2CCc3ccccc3C2)CC1)c1cccnc1

Standard InChI:  InChI=1S/C41H53N7O5/c1-41(2,3)28-43-36(49)25-35(45-40(53)47-22-19-31(20-23-47)38(51)46(4)33-15-10-21-42-26-33)37(50)44-34(17-16-29-11-6-5-7-12-29)39(52)48-24-18-30-13-8-9-14-32(30)27-48/h5-15,21,26,31,34-35H,16-20,22-25,27-28H2,1-4H3,(H,43,49)(H,44,50)(H,45,53)/t34-,35-/m0/s1

Standard InChI Key:  IDYWZJLMUWCKBR-PXLJZGITSA-N

Associated Targets(Human)

20S proteasome 530 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 723.92Molecular Weight (Monoisotopic): 723.4108AlogP: 4.09#Rotatable Bonds: 12
Polar Surface Area: 144.05Molecular Species: NEUTRALHBA: 6HBD: 3
#RO5 Violations: 1HBA (Lipinski): 12HBD (Lipinski): 3#RO5 Violations (Lipinski): 2
CX Acidic pKa: 12.56CX Basic pKa: 4.34CX LogP: 2.87CX LogD: 2.87
Aromatic Rings: 3Heavy Atoms: 53QED Weighted: 0.26Np Likeness Score: -1.13

References

1. Cao Y, Tu Y, Fu L, Yu Q, Gao L, Zhang M, Zeng L, Zhang C, Shao J, Zhu H, Zhou Y, Li J, Zhang J..  (2022)  Metabolism guided optimization of peptidomimetics as non-covalent proteasome inhibitors for cancer treatment.,  233  [PMID:35218994] [10.1016/j.ejmech.2022.114211]

Source